Your medical briefing

Stay current.
Stay focused.

Research, guidelines, and safety alerts for your specialty.

Family Medicine

Recent updates in Family Medicine from the last 30 days.

AllAll updates Research Guidelines Safety alerts

The third paper in a peripheral arterial disease (PAD) series describes the disease's individual-level effects, including chronic pain, functional limitation, loss of independence, and impaired quality of life, along with high risk of major amputation, myocardial infarction, stroke, and death. The paper reports that the burden of PAD falls disproportionately on women, First Nations Peoples, other non-White individuals, financially insecure patients, and those in remote areas, and it recommends improving disease awareness, multidisciplinary care models, testing early screening and medical management, and modifying health-care service access for underserved populations.

Stay current.
Stay focused.

Family Medicine

Series outlines PAD's toll and disparities, calls for care changes

Series highlights underdiagnosis and poor prognosis of peripheral arterial disease

Review outlines updated approach to peripheral arterial disease management

Medicare Advantage Enrollees With Kidney Failure Had Lower Transplant Rates

Colonoscopy at 5 Years Noninferior to 3 Years After High-Risk Adenoma

CREST-2: Carotid Revascularization Did Not Improve Cognition

Class I recall: Baxter Healthcare Corporation: Dextrose Injection, USP, 70 %, 2000 mL bags, Rx Only, Baxter Healthcare Corporat

Short antibiotic course noninferior to long course after orthopedic infection surgery

Review outlines diagnosis and shunt outcomes in idiopathic NPH

Azithromycin Use Rose, Postpartum Infections Fell After Cesarean Trial

Class II recall: Mylan Pharmaceuticals Inc: Prasugrel Tablets, USP, 10mg, Rx only, 30 Tablets in each bottle, Manufactured f

Class II recall: Teva Pharmaceuticals USA, Inc: traZODone Hydrochloride Tablets, USP, 50 mg, Rx only, 100 Tablets, Manufactured

Class I recall: Baxter Healthcare Corporation: 0.9% Sodium Chloride Injection USP 500 mL, VIAFLEX Plastic Containers, with 24 u

Class II recall: Baxter Healthcare Corporation: Vasopressin, in 0.9% Sodium Chloride Injection, 40 units per 100 mL (0.4 units/m

Class II recall: Baxter Healthcare Corporation: Famotidine Injection in Sodium Chloride Injection, 20 mg, 50 mL in GALAXY Single

Class II recall: Baxter Healthcare Corporation: Clindamycin Injection USP in 5% Dextrose, 900 mg per 50 mL (12 mg/mL) in GALAXY

Class II recall: ACCORD HEALTHCARE, INC.: Levothyroxine Sodium Tablets, USP, 175 mcg (0.175 mg), packaged in a) 90-count b

Class II recall: ACCORD HEALTHCARE, INC.: Levothyroxine Sodium Tablets, USP, 150 mcg (0.15 mg), 1000-count bottles, Rx Onl

Class II recall: ACCORD HEALTHCARE, INC.: Levothyroxine Sodium Tablets, USP, 75 mcg (0.075 mg), 1000-count bottles, Rx Onl

Class II recall: ACCORD HEALTHCARE, INC.: Levothyroxine Sodium Tablets, USP, 300 mcg (0.3 mg), 90-count bottles, Rx Only,

Class II recall: ACCORD HEALTHCARE, INC.: Levothyroxine Sodium Tablets, USP, 25 mcg (0.025 mg), 1000-count bottles, Rx Onl

Class II recall: ACCORD HEALTHCARE, INC.: Levothyroxine Sodium Tablets, USP, 50 mcg (0.05 mg), 1000-count bottles, Rx Only

Stay current. Stay focused.

Stay current.
Stay focused.